For other germline risk variants (e.g., ATM serine/threonine kinase [ATM], partner and localizer of BRCA2 [PALB2], and checkpoint kinase 2 [CHEK2]), susceptibility to breast cancer has been estimated to account for less than 50% of cases. This evidence concerns the gene BRCA2 and breast carcinoma.